MedCap AB (publ) (STO:MCAP)
Sweden
· Delayed Price · Currency is SEK 458.50
+12.50 (2.80%)
Jun 27, 2025, 5:29 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2015 - 2020 |
Specialty Pharma | 410.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Pharma Growth | -14.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg1 | 500.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg1 Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Tech | 821.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Tech Growth | 29.15% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medtech Revenue (Post-Q2 2023 Reporting) | 607.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medtech Revenue (Post-Q2 2023 Reporting) Growth | 10.04% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceuticals | 397.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceuticals Growth | -17.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Technology | 820.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Technology Growth | 29.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Devices | 326.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medical Devices Growth | 17.41% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nutrition & Other Food | 253.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nutrition & Other Food Growth | 7.28% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product | 40.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Growth | -0.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg2 | 900.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Revenue seg2 Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2015 - 2020 |
Specialty Pharma Operating Profit | 21.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Pharma Operating Profit Growth | -71.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other and Eliminations from Operating Profit | -24.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other and Eliminations from Operating Profit Growth | -12.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 | -34.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other EBIT seg1 Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Tech Operating Profit | 171.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Tech Operating Profit Growth | 18.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medtech Operating Profit (Post-Q2 2023 Reporting) | 96.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medtech Operating Profit (Post-Q2 2023 Reporting) Growth | 27.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2015 - 2020 |
Specialty Pharma Adjusted EBITDA | 45.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Pharma Adjusted EBITDA Growth | -55.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other and Eliminations from Adjusted EBITDA | -22.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other and Eliminations from Adjusted EBITDA Growth | -6.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Tech Adjusted EBITDA | 224.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Assistive Tech Adjusted EBITDA Growth | 21.67% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medtech Adjusted EBITDA (Post-Q2 2023 Reporting) | 136.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Medtech Adjusted EBITDA (Post-Q2 2023 Reporting) Growth | 22.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2015 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2015 - 2020 |
Sweden | 883.80M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Sweden Growth | 3.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nordic (ex-Sweden) | 476.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Nordic (ex-Sweden) Growth | 29.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe (ex-Nordic) | 402.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe (ex-Nordic) Growth | 1.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of the World | 76.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of the World Growth | 38.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|